YODA 1 NO FURTHER A MYSTERY

In our examine, we were ready to significantly escalate the dose of CX-5461 further than that achieved in the 1st-in-human research in people with hematologic cancers. The RP2D of 475 mg/m2 on times 1, eight, and 15 of a 4-7 days cycle, was depending on phototoxicity, which happened In spite of demanding UV mild avoidance protocols and within the